

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe / Simvastatin Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

<b>Appearance</b>	: powder
<b>Colour</b>	: No data available
<b>Odour</b>	: No data available

Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure. Harmful to aquatic life. Toxic to aquatic life with long lasting effects.

#### GHS Classification

Skin corrosion/irritation : Category 2

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure : Category 1

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 2

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519




ORGANON

## Ezetimibe / Simvastatin Formulation

Version 6.2      Revision Date: 2024/04/06      SDS Number: 28115-00023      Date of last issue: 2023/09/30  
Date of first issue: 2014/11/04

### GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H372 Causes damage to organs through prolonged or repeated exposure.  
H402 Harmful to aquatic life.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves.  
**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.  
P391 Collect spillage.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

### Physical and chemical hazards

Not classified based on available information.

### Health hazards

Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure.

### Environmental hazards

Harmful to aquatic life. Toxic to aquatic life with long lasting effects.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version 6.2      Revision Date: 2024/04/06      SDS Number: 28115-00023      Date of last issue: 2023/09/30  
Date of first issue: 2014/11/04

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 20
Ezetimibe	163222-33-1	>= 10 -< 20
Simvastatin	79902-63-9	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 10

## 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.  
May cause an allergic skin reaction.  
Causes damage to organs through prolonged or repeated exposure.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

## 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Fluorine compounds Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

#### Handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not get on skin or clothing.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version 6.2      Revision Date: 2024/04/06      SDS Number: 28115-00023      Date of last issue: 2023/09/30  
Date of first issue: 2014/11/04

Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

### Storage

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.  
Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PC-TWA	10 mg/m <sup>3</sup>	CN OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Simvastatin	79902-63-9	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: DSEN				
Magnesium stearate	557-04-0	Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.2	2024/04/06	28115-00023	2023/09/30
			Date of first issue: 2014/11/04

---

the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

### 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Cellulose:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

##### Ezetimibe:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 5,000 mg/kg LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal  LD50 (Mouse): > 1,000 - < 2,000 mg/kg Application Route: Intraperitoneal



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

### Simvastatin:

Acute oral toxicity : LD50 (Rat): 5,000 mg/kg  
LD50 (Mouse): 3,800 mg/kg

### Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### Skin corrosion/irritation

Causes skin irritation.

### Components:

#### Ezetimibe:

Species : Rabbit  
Result : No skin irritation

#### Simvastatin:

Species : Rabbit  
Remarks : Moderate skin irritation

#### Magnesium stearate:

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Ezetimibe:

Species : Rabbit  
Result : No eye irritation

#### Simvastatin:

Species : Rabbit  
Remarks : slight irritation

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.2	2024/04/06	28115-00023	2023/09/30
			Date of first issue: 2014/11/04

---

### Magnesium stearate:

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

### Respiratory or skin sensitisation

#### Skin sensitisation

May cause an allergic skin reaction.

#### Respiratory sensitisation

Not classified based on available information.

### Components:

#### Ezetimibe:

Test Type : Maximisation Test  
Species : Guinea pig  
Result : negative

#### Simvastatin:

Assessment : Probability or evidence of skin sensitisation in humans  
Result : positive

### Magnesium stearate:

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

### Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Metabolic activation: with and without metabolic activation  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

### Simvastatin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### Ezetimibe:

Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

#### Simvastatin:

Species : Mouse  
Application Route : Oral  
Exposure time : < 92 weeks  
Target Organs : Harderian gland  
Tumor Type : Liver, Lungs  
Remarks : The significance of these findings for humans is not certain.

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Tumor Type : Liver, Thyroid  
Remarks : The significance of these findings for humans is not certain.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Cellulose:

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### **Ezetimibe:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1,000 mg/kg body weight  
Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects

### **Simvastatin:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight  
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight  
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

Result: Teratogenic potential  
Remarks: Based on data from similar materials

### Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

### Components:

#### Simvastatin:

Target Organs : Liver, muscle, optic nerve, Eye  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

#### Ezetimibe:

Species : Dog  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Rat

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

NOAEL : 1,500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Remarks : No significant adverse effects were reported

### Simvastatin:

Species : Rat  
NOAEL : 5 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Eye

Species : Rabbit  
NOAEL : 30 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Target Organs : Liver, Kidney

### Magnesium stearate:

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version 6.2      Revision Date: 2024/04/06      SDS Number: 28115-00023      Date of last issue: 2023/09/30  
Date of first issue: 2014/11/04

---

### Components:

#### **Ezetimibe:**

Not applicable

### **Experience with human exposure**

### Components:

#### **Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

#### **Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
Ingestion : Target Organs: Liver  
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea  
Target Organs: Musculo-skeletal system

---

## 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

### Components:

#### **Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

#### **Ezetimibe:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0.317



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l  
Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

NOEC: 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

### Simvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l  
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 96 h

Toxicity to microorganisms : EC50: > 30 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.2	2024/04/06	28115-00023	2023/09/30
			Date of first issue: 2014/11/04

---

Method: OECD Test Guideline 209

NOEC: 21 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

#### Cellulose:

Biodegradability : Result: Readily biodegradable.

#### Ezetimibe:

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111

### Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

### Magnesium stearate:

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

##### Ezetimibe:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

##### Simvastatin:

Partition coefficient: n-octanol/water : log Pow: > 4.07

##### Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

#### Components:

##### Ezetimibe:

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

### Other adverse effects

No data available

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

### 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Simvastatin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Ezetimibe, Simvastatin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Simvastatin)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

### GB 6944/12268

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	9
Marine pollutant	:	no

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 15. REGULATORY INFORMATION

### National regulatory information

#### Law on the Prevention and Control of Occupational Diseases

#### Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

#### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## 16. OTHER INFORMATION

Revision Date : 2024/04/06

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CN OEL	:	Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
6.2	2024/04/06	28115-00023	Date of first issue: 2014/11/04

---

ACGIH / TWA : 8-hour, time-weighted average  
CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN